8.6 Malignant Hyperthermia Pathophysiology & Crisis Response

8.6 Malignant Hyperthermia Pathophysiology & Crisis Response

Malignant Hyperthermia (MH) is an acute, life-threatening pharmacogenetic crisis of skeletal muscle that represents one of the most critical emergencies in perioperative medicine. For the Certified Anesthesia Technologist, rapid recognition of the physiological signs, immediate technical mobilization of the emergency MH cart, flawless reconstitution of dantrolene formulations, and execution of circuit decontamination protocols are vital for patient survival.

---

Genetic Etiology, Receptor Mutations & Molecular Pathophysiology

The Ryanodine Receptor 1 (RYR1) & Calcium Release Kinetics

Malignant hyperthermia is transmitted as an autosomal dominant trait with variable penetrance and expressivity:

• The RYR1 Gene: Mutations in the Ryanodine Receptor Type 1 (RYR1) gene, located on chromosome 19q13.1, account for 70% to 80% of all MH-susceptible families. The RYR1 protein is a massive homotetrameric calcium release channel embedded in the terminal cisternae of the sarcoplasmic reticulum (SR) of skeletal muscle.
• Secondary Mutations: Pathogenic mutations also occur in the CACNA1S gene on chromosome 1q32 (encoding the alpha-1S subunit of the L-type voltage-gated calcium channel / dihydropyridine receptor [DHPR]) and the STAC3 gene.
• Associated Myopathies: Strong clinical associations exist with Central Core Disease (CCD), King-Denborough syndrome, and Multiminicore disease.
• Diagnostic Standard: The gold standard diagnostic confirmation is the Caffeine-Halothane Contracture Test (CHCT), which measures muscle strip tension in response to caffeine and halothane on a freshly biopsied vastus lateralis muscle specimen.

MOLECULAR CASCADE OF MALIGNANT HYPERTHERMIA:

[ Volatile Anesthetic or Succinylcholine Exposure ]
                       |
                       v
[ Mutated RYR1 Channel Locked in Open Conformation ]
                       |
                       v
[ Massive Uncontrolled Ca2+ Efflux from SR into Myoplasm ]
                       |
                       v
[ Overwhelms SERCA Reuptake Pump; Sustained Troponin C Binding ]
                       |
                       v
[ Uninhibited Actin-Myosin Cross-Bridge Cycling (No Depolarization Needed) ]
                       |
                       +-----------------------------------+
                       |                                   |
                       v                                   v
             MASSIVE HYPERMETABOLISM             CELLULAR ATP DEPLETION
        (O2 Depletion, Extreme CO2 & Heat)       (Membrane Pump Failure)
                       |                                   |
                       v                                   v
           Mixed Respiratory/Metabolic Acidosis       RHABDOMYOLYSIS
                Severe Hyperthermia               (K+, CK, Myoglobin Leakage)

Hypermetabolic Cascade, Rhabdomyolysis & Electrolyte Collapse

Under resting conditions, intracellular myoplasmic calcium ([Ca2+]) is maintained at < 0.1 μM. During normal muscle excitation-contraction coupling, action potential depolarization activates the voltage-sensing DHPR, which mechanically opens the RYR1 channel, transiently releasing Ca2+ into the myoplasm. Calcium binds troponin C, unshielding actin and allowing myosin cross-bridge cycling. Relaxation occurs when the SERCA (Ca2+-ATPase) pump rapidly re-sequesters calcium back into the sarcoplasmic reticulum.

In MH-susceptible individuals exposed to a chemical trigger, the mutated RYR1 channel locks into a pathologically open conformation, causing an uncontrolled, massive flood of calcium into the myoplasm. The consequences are catastrophic:

1. Continuous Cross-Bridge Cycling: The flood of calcium overwhelms SERCA pumps and sustains continuous actin-myosin contraction without requiring sarcolemmal electrical depolarization.
2. Extreme Hypermetabolism: Cross-bridge cycling and hyperactive SERCA pumps consume massive amounts of ATP. Aerobic cellular respiration accelerates, generating tremendous volumes of carbon dioxide (CO2) and thermal heat.
3. Profound Mixed Acidosis: As oxygen consumption outstrips capillary delivery, cellular metabolism shifts to anaerobic glycolysis, producing massive lactic acidosis. The patient develops profound mixed respiratory and metabolic acidosis (pH < 7.15, PaCO2 > 60 to 90 mmHg, base deficit < -10 mEq/L, lactate > 5 to 10 mmol/L).
4. Cellular Energy Exhaustion & Rhabdomyolysis: Complete ATP depletion deprives the sarcolemmal Na+/K+ ATPase pump of fuel, causing loss of cell membrane integrity. Muscle cells burst, releasing massive intracellular contents into the systemic circulation:
   • Potassium (K+): Acute, severe hyperkalemia (>6 to 9 mEq/L), triggering peaked T waves, widening QRS complexes, ventricular fibrillation, and asystolic cardiac arrest.
   • Creatine Kinase (CK): Soars to levels >20,000 to >100,000 units/L, peaking 12 to 24 hours post-crisis.
   • Myoglobin: Free myoglobin filters across the glomerulus, precipitating in renal tubules and causing acute tubular necrosis (ATN) and acute renal failure.

---

Triggering Agents vs Safe Non-Triggering Anesthetic Agents

Absolute avoidance of triggers is mandatory in any patient with suspected or confirmed MH susceptibility:

---

Clinical Manifestation Timeline & Diagnostic Signs

The clinical presentation of MH follows a characteristic physiological timeline:

1. Earliest, Most Sensitive Sign: Refractory Hypercarbia (PetCO2 > 50 to 70+ mmHg): The massive metabolic generation of CO2 by uninhibited skeletal muscle contraction rapidly overwhelms the patient's ventilation. Even when the provider doubles or triples minute ventilation, end-tidal CO2 continues to rise relentlessly. The CO2 absorbent canister becomes hot to the touch and exhausts rapidly because of the enormous CO2 load.
2. Early Cardiovascular Sign: Unexplained Tachycardia & Tachypnea: Sinus tachycardia is the earliest cardiovascular sign, driven by profound sympathetic activation and hypercarbia. Spontaneously breathing patients exhibit rapid, deep tachypnea.
3. Masseter Muscle Rigidity (MMR / "Jaws of Steel"): An exaggerated, sustained contracture of the masseter muscles following succinylcholine administration that prevents mouth opening for endotracheal intubation. Mild masseter tension can occur normally after succinylcholine, but true "jaws of steel" is a warning sign: roughly half of patients with severe masseter rigidity are later found to be MH-susceptible.
4. Generalized Muscle Rigidity: Severe, board-like muscle stiffness that persists even after high doses of non-depolarizing muscle relaxants are administered (because the contraction originates distal to the neuromuscular junction at the sarcoplasmic reticulum).
5. Electrocardiographic Signs of Hyperkalemia: Peaked, symmetrical T waves, widening QRS complexes, ventricular ectopy, ventricular tachycardia, and cardiac arrest.
6. Late Manifestation: Hyperthermia (Temperature Rising 1°C to 2°C Every 5 Minutes): Core body temperature accelerates rapidly, frequently reaching 41°C to 43°C (106°F to 110°F). Fever is a LATE sign; waiting for hyperthermia before initiating dantrolene dramatically increases mortality!
7. Late Consequences: Cola-colored urine (myoglobinuria), acute renal failure, disseminated intravascular coagulation (DIC), compartment syndrome, and multi-organ system failure.

---

Emergency MHAUS Treatment Protocol & Anesthesia Technologist Action Sequence

When an MH crisis is declared, the surgical and anesthesia team must execute the MHAUS Emergency Treatment Protocol without hesitation:

EMERGENCY MALIGNANT HYPERTHERMIA TREATMENT ALGORITHM:

[ 1. HALT TRIGGERS & NOTIFY SURGEON ] ---> Conclude or abort procedure immediately
                    |
                    v
[ 2. MOBILIZE EMERGENCY MH CART & PERSONNEL ] ---> Call MHAUS Hotline: 1-800-MH-HYPER
                    |
                    v
[ 3. HYPERVENTILATE WITH 100% O2 AT >= 10 L/MIN & INSERT ACTIVATED CHARCOAL FILTERS ]
                    |
                    v
[ 4. ADMINISTER DANTROLENE SODIUM IV BOLUS IMMEDIATELY (2.5 mg/kg) ]
                    |
                    v
[ 5. TREAT ACUTE HYPERKALEMIA ] ---> Calcium Chloride, Sodium Bicarb, Insulin + D50
                    |
                    v
[ 6. ACTIVE COOLING MEASURES ] ---> Cold IV Saline, Ice Packs; HALT COOLING AT 38.0°C
                    |
                    v
[ 7. MAINTAIN URINE OUTPUT > 2 mL/kg/hr ] ---> Insert temp Foley, fluids, bicarb
                    |
                    v
[ 8. POST-CRISIS ICU CARE & MONITOR FOR RECRUDESCENCE (24-48 HOURS) ]

Step 1: Discontinue Triggering Agents & Alert Surgical Team

• Immediately shut off all volatile anesthetic vaporizers and remove vaporizers from the manifold if feasible. Discontinue any running succinylcholine infusion.
• Inform the surgical team immediately: surgery must be concluded or aborted at the earliest safe opportunity.

Step 2: Call for the Emergency MH Cart & Alert Personnel

• Call out: "Malignant Hyperthermia Crisis!" Mobilize all available operating room technicians, nurses, and anesthesia providers. Assign specific roles: dantrolene reconstitution, ice retrieval, blood gas sampling, and documentation.
• Contact the MHAUS Emergency Hotline: 1-800-MH-HYPER (1-800-644-9737) for real-time consultation with an MH expert.

Step 3: Hyperventilate with 100% O2 & Insert Activated Charcoal Filters

• Increase fresh gas flow of 100% oxygen to at least 10 L/min.
• Increase minute ventilation to 2 to 3 times the patient's baseline to wash out massive CO2 production.
• Activated Charcoal Filter Canisters (Vapor-Clean): The anesthesia technologist immediately places two activated charcoal filter canisters onto the inspiratory and expiratory ports of the anesthesia workstation breathing circuit. These specialized filters adsorb residual volatile anesthetic vapors, driving circuit volatile concentrations down to < 5 ppm in under 2 minutes. This eliminates the dangerous historical practice of wasting critical time swapping out the entire anesthesia machine! If filters are not immediately available, flush the machine at 10 L/min fresh gas flow without delaying dantrolene.

Step 4: Administer Dantrolene Sodium Immediately

Dantrolene sodium is a specific ryanodine receptor-1 antagonist. It directly binds to the RYR1 channel on the sarcoplasmic reticulum, inhibiting calcium efflux into the myoplasm and aborting the hypermetabolic cross-bridge cycling cascade.

• Initial Loading Dose: 2.5 mg/kg IV rapid bolus through a large-bore intravenous line.
• Repeat Dosing: Repeat boluses of 1.0 to 2.5 mg/kg every 5 to 10 minutes until hypercarbia, tachycardia, muscle rigidity, and hyperthermia resolve. While typical cumulative doses are 2.5 to 10 mg/kg, doses exceeding 20 to 30 mg/kg may be necessary in refractory crises.

Formulations: Traditional Dantrolene vs. Ryanodex

The anesthesia technologist must master the distinct physical preparation protocols of the two available formulations:

Step 5: Treat Life-Threatening Hyperkalemia

Acute hyperkalemic cardiac arrest is the primary cause of immediate death in MH crises:

• Calcium Chloride: 10 mg/kg IV (10% solution, ~1000 mg in adults) to immediately stabilize cardiac myocyte membranes against hyperkalemic depolarization. (Alternatively, calcium gluconate 30 mg/kg IV).
• Sodium Bicarbonate: 1 to 2 mEq/kg IV bolus; buffers profound metabolic acidosis and shifts potassium ions intracellularly.
• Insulin and Glucose: 10 units regular insulin IV combined with 50 mL of 50% Dextrose (D50, 25 g) IV to transport potassium into the intracellular fluid compartment.

Step 6: Active Cooling Measures & The 38.0°C Cutoff

• Infuse iced cold intravenous saline (0.9% NaCl, 4°C, 1000 mL boluses up to 2000 to 3000 mL).
• Apply ice packs to high vascular flow regions: bilateral axillae, groin, and lateral neck; wrap torso in cooling blankets.
• Perform cold saline cavity lavage: stomach via nasogastric tube, bladder via Foley catheter, and open surgical cavities if present.
• THE MANDATORY COOLING CUTOFF: HALT all active cooling measures when core body temperature reaches 38.0°C (100.4°F)! Failing to stop active cooling at 38.0°C produces severe hypothermic overshoot, causing hypothermic ventricular arrhythmias, coagulopathy, shivering, and rebound vasoconstriction.

Step 7: Renal Preservation & Antidysrhythmic Rules

• Urine Output Target: Insert a temperature-sensing Foley catheter. Maintain urine output > 2 mL/kg/hr with IV hydration, mannitol (already present in traditional dantrolene), or furosemide (0.5 to 1.0 mg/kg IV) to prevent intraluminal myoglobin cast crystallization and acute tubular necrosis.
• Alkalinize the Urine: Sodium bicarbonate administration maintains urine pH > 7.0, increasing the solubility of filtered myoglobin.
• ABSOLUTE CONTRAINDICATION: Calcium Channel Blockers (e.g., verapamil, diltiazem) are strictly prohibited! Co-administration of calcium channel blockers with dantrolene triggers catastrophic myocardial depression, intractable hyperkalemia, and cardiovascular collapse.
• Safe Antidysrhythmics: Beta-blockers (esmolol), amiodarone, or lidocaine.

Step 8: Post-Crisis ICU Monitoring & Recrudescence

• Following stabilization, transfer the patient to an Intensive Care Unit for continuous hemodynamic, core temperature, and laboratory monitoring for at least 24 hours.
• Recrudescence: Malignant hyperthermia recurs in roughly 20% to 25% of cases, most often within the first 24 hours after the initial episode. Risk factors include delayed initial dantrolene administration, large muscle mass, and severe initial temperature elevations.
• Maintenance Therapy: Continue maintenance dantrolene at 1.0 mg/kg IV every 4 to 6 hours (or a continuous IV infusion of 0.25 mg/kg/hr) for at least 24 hours.
• Serial Labs: Monitor serial arterial blood gases, serum potassium, lactate, serial creatine kinase (peaks at 14 to 24 hours), coagulation profiles (PT/INR, PTT, fibrinogen, D-dimer to monitor for DIC), and urine myoglobin.